Vaccine Safety Conference Session 2011

Spread the love

Uploaded on Nov 4, 2011

 

ORIGINAL SAFETY CONFERENCE SESSION HERE

Dr. Christopher Exley- The Systemic Toxicity of Aluminium Adjuvants.

Dr. Christopher Exley is the Reader in Bioinorganic Chemistry at The Birchall Centre, Keele University in Staffordshire and Honorary Professor at the UHI Millennium Institute. Exley is a biologist (University of Stirling) with a PhD in the ecotoxicology of aluminium (University of Stirling). His research career (1984-present) has focused upon an intriguing paradox; ‘how the third most abundant element of the Earth’s crust (aluminium) is non-essential and largely inimical to life’. Investigating this mystery has required research in myriad fields from the basic inorganic chemistry of the reaction of aluminium and silicon to the potentially complex biological availability of aluminium in humans. Exley is also fascinated by the element silicon in relation to living things which, as the second most abundant element of the Earth’s crust, is also almost devoid of biological function. One possible function of silicon is to keep aluminium out of biology (biota) and this area of study forms a large part of Exley’s research.

 

Christopher A. Shaw, Ph.D, Professor

Uploaded on Oct 6, 2011

Aluminum as a Neurotoxin: the Evidence from Cell Culture, in Vivo

Dr. Christopher Shaw is a Professor in the Department of Ophthalmology and Visual Sciences at the University of British Columbia and holds cross appointments with the Department of Experimental Medicine and the Graduate Program in Neuroscience. He is the author of more than 100 peer-reviewed articles as well as numerous book chapters and special reviews. Shaw has edited four books on neuroscience themes. The main focus of his research has been on the Guamanian neurological disease spectrum, ALS-parkinsonism dementia complex (ALS-PDC). Recent work in the laboratory has developed animal models of the disease that are able to recapitulate all the essential behavioural and pathological features. The model is also being used to understand gene-toxin interactions, define neurodegeneration pathways involved, and to attempt therapeutic interventions at early, mid and late time points. Work in the laboratory also provided one of the first models of aluminum adjuvant-induced neuropathology and these studies have become a new research direction. He is the founder and a former director of Neurodyn, a biotechnology company based out of Prince Edward Island. Neurodyn’s efforts are directed at early phase detection and treatment for age-related neurological disorders. He has two children. The youngest has not been vaccinated. Produced by Northica.media for NVIC.

 

Dr. Russell Blaylock, MD, CCN

Uploaded on Nov 22, 2011

THE CENTRAL ROLE OF IMMUNOEXCITOTOXICITY IN ALUMINUM AND MERCURY-CONTAINING ADJUVANT-TRIGGERED NEURODEVELOPMENTAL AND NEURODEGENERATIVE DISORDERS

Dr. Russell Blaylock is a board certified neurosurgeon, author and lecturer. He attended the Louisiana State University School of Medicine in New Orleans and completed his general surgical internship and neurosurgical residency at the Medical University of South Carolina in Charleston, South Carolina. During his residency training he worked with the eminent neurosurgeon, Dr. Ludwig Kempe. Together they developed the transcallosal removal of intraventricular tumors, a technique still used today. For the past 25 years he has practiced neurosurgery in addition to having a nutritional practice. He recently retired from his neurosurgical duties to devote his full attention to nutritional studies and neuroscience research.

Blaylock has authored three books on nutrition and wellness: Excitotoxins: The Taste That Kills, Health and Nutrition Secrets That Can Save Your Life and Natural Strategies for The Cancer Patient. He co-authored the book Cellular and Molecular Biology of Autism Spectrum Disorders with Dr. Anna Strunecka and written over 40 papers for peer-reviewed journals. Blaylock serves on the editorial staff of the Fluoride Journal, the Journal of the American Physicians and Surgeons and the Journal of the American Nutriceutical Association. Blaylock has been appointed to serve on the Scientific Advisory Board of the Life Extension Foundation. He is the 2004 recipient of the Integrity in Science Award granted by the Weston A. Price Foundation. An in-demand guest for radio and television programs, he lectures extensively to both lay and professional medical audiences on a variety of nutrition-related subjects. He previously served as clinical assistant professor of neurosurgery at the University of Mississippi Medical Center in Jackson, Miss. and is currently a visiting professor of biology at Belhaven University, also in Jackson.

 

Dr. Andrew Wakefield

Uploaded on Jan 9, 2012

Andrew Wakefield, MB, BS, FRCS, FRCPath
AUTISM AND VACCINES: A RESEARCH STRATEGY FOCUSED ON CAUSE

Filmed at the Vaccine Safety Conference, 2011. For more information please goto www.vaccinesafetyconference.com

Dr. Andrew Wakefield is an academic gastroenterologist. He received his medical degree from St. Mary’s Hospital Medical School (part of the University of London) in 1981. He is the fourth generation of his family to have studied medicine at that teaching hospital.

He pursued a career in gastrointestinal surgery with a particular interest in inflammatory bowel disease. He qualified as Fellow of the Royal College of Surgeons in 1985 and in 1996 was awarded a Wellcome Trust Traveling Fellowship to study small-intestinal transplantation in Toronto, Canada. Wakefield was made a Fellow of the Royal College of Pathologists in 2001. He has published over 145 original scientific articles, book chapters, and invited scientific commentaries. He recently authored the bestselling book Callous Disregard, chronicling his experiences of challenging public health policy and pharmaceutical industry interests in the UK.

In the pursuit of possible links between childhood vaccines, intestinal inflammation, and neurologic injury in children, Wakefield lost his job in the Department of Medicine at London’s Royal Free Hospital, his country, his career, and his medical license.

Wakefield is currently founder and executive director of Strategic Autism Initiative, a Texas-based charity focused on research into autism causation. He is also managing partner and scientific editor of The Autism File Global, a special interest magazine.

Vaccine Safety Conference Opening Address – Barbara Loe Fisher

 

Dr. Vicky Debold, PhD, RN

Dr. Vicky Pebsworth Debold is an NVIC board member and volunteer Director of Research and Patient Safety. She has worked with NVIC since 2006 on vaccine safety analytical and education projects.

Debold has been employed in the health care field for more than 30 years as an ICU nurse, health care administrator and health policy analyst primarily focusing on pediatrics and patient safety. Currently, she is a Research Scientist and Affiliate Faculty member at George Mason University in the Health Administration and Policy Department where she teaches Health Services Research Methods.

Since 2008, she has served as the consumer voting member of the Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee (VRBPAC). Additionally, she has worked for the Vaccine Safety Working Group (Epidemiology and Implementation Subcommittees) of the National Vaccine Advisory Committee (NVAC). She also serves as the consumer representative to the independent H1N1 Vaccine Safety Risk Assessment Working Group and has been a consultant to the Centers for Disease Control and Prevention Board of Scientific Counselors.

In 2009, she provided testimony to the Institute of Medicine’s committee on the Review of National Vaccine Plan Priorities addressing two topics: informed vaccine decision making and enhancing the safety of vaccines and vaccination practices.

Debold previously worked as a health policy analyst for the U.S. Congress’s Physician Payment Review Commission; for the Michigan Health and Safety Coalition; and for the Michigan State Commission on Patient Safety. Additionally, she was an Assistant Professor at the University of Michigan and an Associate Professor and Director of the Health Systems Management Program at the University of Detroit, Mercy.

She has successfully competed for research funding from the Robert Wood Johnson Foundation, the University of Michigan Health Systems Health Services Research Initiative, and the Health Care Financing Administration. Her analyses and papers have been published in the Journal of the American Medical Association, Advances in Patient Safety: New Directions and Alternative Approaches, Journal of the American Academy of Physician Assistants, and Critical Care Nursing Clinics of North America.

She received her doctoral degree from the University of Michigan (1999) — School of Public Health (Health Services Organization and Policy) and School of Nursing (Health Systems Administration). She was a University of Michigan Regent’s Fellow and completed a post-doctoral fellowship in health systems research.

 

 

Dr. Romain Gherardi
Nanosized particles injected into muscle slowly disseminate within phagocytes

Dr. Romain K. Gherardi is a French specialist of neuromuscular diseases. He graduated in clinical Neurology and Pathology, and has been a Professor since 1990. He is working at the Henri Mondor hospital, the second largest hospital of Assistance Publique- Hôpitaux de Paris, located in Créteil and depending of Paris-Est University. He heads the department of Histology that includes both Neuropathologic and Clinical activities in the setting of a Neuromuscular disease reference center. He also heads an experimental research team entitled ‘Cellular interactions in the Neuromuscular system” (INSERM U955-E10) at the Institut Mondor de Recherche Biomédicale (IMRB).

From 1983 to 2010, Gherardi has published 290 articles indexed in PubMed, and monitored 14 PhD and 10 MSc students on the topic of biology, pathology and clinics of the nervous and muscular system. He previously studied several immuno-inflammatory and toxic neuromuscular disorders (almitrine neuropathy, zidovudine myopathy, statin myopathy, etc). He is currently working on innate immune reactions to myoinjury, biodistribution of nanoparticles, and pathophysiology of ‘macrophagic myofasciitis” a neurologic disease linked to the long term persistence of Alum adjuvant in monocyte/macrophage lineage cells.

Gherardi is reviewer for Science, N Engl J Med, Lancet, Ann Neurol, Arthritis Rheum, Stem Cells, Stem Cell Dev, Neuromuscular Disord, Muscle Nerve, etc. On the topic of macrophagic myofasciitis, he was an invited speaker by the Centers for Disease Control, WHO Geneva, French government agencies, the French Parliament committee on Gulf War syndrome, and a variety of national and international scientific and medical societies.

Vaccine Safety Conference Session 13 – Dr. Yehuda Shoenfeld, MD, FRCP
VaccineSafetyConf
VaccineSafetyConf
604
12,380 views
Uploaded on Dec 28, 2011

ASIA – Autoimmune (Auto-Inflammatory) Syndrome Induced by Adjuvant: A New Syndrome to be Defined

Dr. Yehuda Shoenfeld is the head of the Department of Medicine at the Tel Aviv University since 1984 (age 36). Has founded and is heading the Center for Autoimmune Diseases since 1985 – at the largest hospital in Israel- the Sheba Medical Center, which is affiliated to the Sackler Faculty of Medicine in the Tel-Aviv University.

Shoenfeld is the Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases in Tel-Aviv University. His clinical and scientific work focuses on Autoimmune Rheumatic Diseases. He has published over 1600 papers in journals such as New Eng J Med, Nature, Lancet, Proc Nat Acad Scie, J Clin Invest, J Immunol, Blood, FASEB, J Exp Med, Circulation, Cancer and others. His articles have had over 20,000 citations until 2009. He has authored and edited 25 books, some of which became cornerstones in science and clinical practice, such as “The Mosaic of Autoimmunity”, “Infections and Autoimmunity”, the textbook “Autoantibodies” and “Diagnostic Criteria of Autoimmune Diseases”, all of which were published by Elsevier and sold by thousands.

He is on the editorial board of 43 journals in the field of Rheumatology, and Autoimmunity and is the founder and the editor of the IMAJ (Israel Medical Association Journal) the representative journal of Science and Medicine in the English language in Israel. Shoenfeld is also the founder and Editor of the “Autoimmunity Reviews” (Elsevier) (Impact factor 6.2). He has written over three hundred chapters in different books. For the last 20 years Shoenfeld has been the Editor of “Harefuah” — The Israel journal in medicine (Hebrew) and edited the Israel Medical Encyclopedia (10 volumes, 5000 items). He has organized over 20 International Congresses in Autoimmunity.

Recently he has opened the new Zabludowicz Center for Autoimmune Diseases in The Chaim Sheba medical Center.